• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BofA Securities initiated coverage on Madrigal Pharmaceuticals with a new price target

    4/22/24 7:39:05 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    BofA Securities initiated coverage of Madrigal Pharmaceuticals with a rating of Underperform and set a new price target of $150.00
    Get the next $MDGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    2/26/2024$155.00Neutral → Sell
    B. Riley Securities
    More analyst ratings

    $MDGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bate Kenneth was granted 715 shares, increasing direct ownership by 37% to 2,627 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:45:22 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levy Richard S was granted 715 shares, increasing direct ownership by 3% to 21,197 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:42:30 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fouse Jacqualyn A was granted 203 shares, increasing direct ownership by 23% to 1,097 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:39:48 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care